Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine

Linda B. Adams, Indu Sinha, Scott G. Franzblau, James L. Krahenbuhl, Reeta T. Mehta

Research output: Contribution to journalArticlepeer-review

66 Scopus citations

Abstract

The therapeutic efficacy of liposomal clofazimine (L-CLF) was studied in mice infected with Mycobacterium tuberculosis Erdman. Groups of mice were treated with either free clofazimine (F-CLF), L-CLF, or empty liposomes twice a week for five treatments beginning on day 1 (acute), day 21 (established), or day 90 (chronic) postinfection. One day after the last treatment, the numbers of CFU of M. tuberculosis in the spleen, liver, and lungs were determined. F-CLF at the maximum tolerated dose of 5 mg/kg of body weight was ineffective; however, 10-fold-higher doses of L-CLF demonstrated a dose response with significant CFU reduction in all tissues without any toxic effects. In acutely infected mice, 50 mg of L-CLF/kg reduced CFU 2 to 3 log units in all three organs. In established or chronic infection, treated mice showed no detectable CFU in the spleen or liver and 1- to 2-log-unit reduction in the lungs. A second series of L-CLF treatments cleared M. tuberculosis in all three tissues. L-CLF appears to be bactericidal in the liver and spleen, which remained negative for M. tuberculosis growth for 2 months. Thus, L-CLF could be useful in the treatment of tuberculosis.

Original languageEnglish (US)
Pages (from-to)1638-1643
Number of pages6
JournalAntimicrobial agents and chemotherapy
Volume43
Issue number7
DOIs
StatePublished - Jul 1999

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine'. Together they form a unique fingerprint.

Cite this